Analyst Price Target is $26.50
▲ +3,685.71% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Medivir AB (publ) in the last 3 months. The average price target is $26.50, with a high forecast of $50.00 and a low forecast of $3.00. The average price target represents a 3,685.71% upside from the last price of $0.70.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Medivir AB (publ).
Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.